Deforolimus (BioDeep_00000010492)

   

Volatile Flavor Compounds


代谢物信息卡片


Ridaforolimus (Deforolimus, MK-8669)

化学式: C53H84NO14P (989.5629134)
中文名称: 息斯敏
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OP(=O)(C)C)C)C)O)OC)C)C)C)OC
InChI: InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

描述信息

L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EG - Mammalian target of rapamycin (mtor) kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor
Same as: D08900

同义名列表

6 个代谢物同义名

Ridaforolimus (Deforolimus, MK-8669); 42-(Dimethylphosphinate)rapamycin; Ridaforolimus; Deforolimus; AP 23573; AP 23573



数据库引用编号

14 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Samantha S Eckley, Johanna M Buschhaus, Brock A Humphries, Tanner H Robison, Kathryn E Luker, Gary D Luker. Short-Term Environmental Conditioning Enhances Tumorigenic Potential of Triple-Negative Breast Cancer Cells. Tomography (Ann Arbor, Mich.). 2019 12; 5(4):346-357. doi: 10.18383/j.tom.2019.00019. [PMID: 31893233]
  • Didier Frappaz, Sara M Federico, Andrew D J Pearson, Lia Gore, Margaret E Macy, Steven G DuBois, Isabelle Aerts, Robert Iannone, Ryan Geschwindt, Arne Van Schanke, Rui Wang, Birgit Geoerger. Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. European journal of cancer (Oxford, England : 1990). 2016 07; 62(?):9-17. doi: 10.1016/j.ejca.2016.03.084. [PMID: 27185573]
  • Matthew Zibelman, Yu-Ning Wong, Karthik Devarajan, Lois Malizzia, Alycia Corrigan, Anthony J Olszanski, Crystal S Denlinger, Susan K Roethke, Colleen H Tetzlaff, Elizabeth R Plimack. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Investigational new drugs. 2015 Oct; 33(5):1040-7. doi: 10.1007/s10637-015-0261-3. [PMID: 26091915]
  • Rachel M Squillace, David Miller, Scott D Wardwell, Frank Wang, Tim Clackson, Victor M Rivera. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. International journal of oncology. 2012 Aug; 41(2):425-32. doi: 10.3892/ijo.2012.1487. [PMID: 22614157]
  • Laetitia Coutte, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre, Eric Raymond. [PI3K-AKT-mTOR pathway and cancer]. Bulletin du cancer. 2012 Feb; 99(2):173-80. doi: 10.1684/bdc.2011.1384. [PMID: 21742593]
  • Antonella Perotti, Alberta Locatelli, Cristiana Sessa, Dagmar Hess, Lucia Viganò, Giuseppe Capri, Michela Maur, Thomas Cerny, Sara Cresta, Federico Rojo, Joan Albanell, Silvia Marsoni, Irene Corradino, Lori Berk, Victor M Rivera, Frank Haluska, Luca Gianni. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Oct; 28(30):4554-61. doi: 10.1200/jco.2009.27.5867. [PMID: 20855840]
  • C Sessa, D Tosi, L Viganò, J Albanell, D Hess, M Maur, S Cresta, A Locatelli, R Angst, F Rojo, N Coceani, V M Rivera, L Berk, F Haluska, L Gianni. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Jun; 21(6):1315-1322. doi: 10.1093/annonc/mdp504. [PMID: 19901013]
  • Jesus Rodriguez-Pascual, Elaine Cheng, Pablo Maroto, Ignacio Duran. Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. Anti-cancer drugs. 2010 Jun; 21(5):478-86. doi: 10.1097/cad.0b013e32833760bf. [PMID: 20401967]
  • C Dreyer, E Raymond, S Faivre. [Targeted therapies and their indications in solid neoplasias]. La Revue de medecine interne. 2009 May; 30(5):416-24. doi: 10.1016/j.revmed.2008.12.022. [PMID: 19299048]
  • Christine M Hartford, Apurva A Desai, Linda Janisch, Theodore Karrison, Victor M Rivera, Lori Berk, John W Loewy, Hedy Kindler, Walter M Stadler, Heather L Knowles, Camille Bedrosian, Mark J Ratain. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Feb; 15(4):1428-34. doi: 10.1158/1078-0432.ccr-08-2076. [PMID: 19228743]
  • Gail M Wilkes. Drug essentials mTOR inhibitors. Oncology (Williston Park, N.Y.). 2008 Apr; 22(4 Suppl Nurse Ed):43-4. doi: NULL. [PMID: 19856563]
  • S Antonsen, F B Pedersen, P Wang. Detection of neutrophil granulocytes in peritoneal dialysis effluents by means of the Cytur-test. Danish Study Group on Peritonitis in Dialysis (DASPID). Scandinavian journal of clinical and laboratory investigation. 1991 Apr; 51(2):149-54. doi: 10.1080/00365519109091101. [PMID: 2042020]